MODAG GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.modag.net
Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138b (TEV-56286)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 54
- Registration Number
- NCT05532358
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04685265
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT04208152
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
News
No news found